AgingResearch.NewsJoin free

Coronavac + IIV4 + PPV23

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funder: Beijing Municipal Science and Technology Commission
  • Human trial1

Outcomes

2

Immune response

upin humans1

1 study

  1. Coronavac + IIV4 + PPV23 induces immune response in humans.

    “In adults ≥60, all vaccine combinations were immunogenic, suggesting a flexible vaccination approach.”

    Human trialhealthy adults

    Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study

    Frontiers in immunologyAug 20, 2024

More on Immune response

Adverse events

no changein humans1

1 study

  1. Coronavac + IIV4 + PPV23 has no effect on adverse events in humans.

    “Co-administration of a third dose of CoronaVac, IIV4, and PPV23 in any combination was safe.”

    Human trialhealthy adultsn = 636

    Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study

    Frontiers in immunologyAug 20, 2024

Latest

Related